- Home
- UFCS vs ABVX Comparison
UFCS vs ABVX Comparison
Compare UFCS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- ABVX
- Stock Information
- Founded
- UFCS 1946
- ABVX 2013
- Country
- UFCS United States
- ABVX France
- Employees
- UFCS N/A
- ABVX N/A
- Industry
- UFCS Property-Casualty Insurers
- ABVX
- Sector
- UFCS Finance
- ABVX
- Exchange
- UFCS Nasdaq
- ABVX Nasdaq
- Market Cap
- UFCS 642.7M
- ABVX 722.3M
- IPO Year
- UFCS N/A
- ABVX N/A
- Fundamental
- Price
- UFCS $28.95
- ABVX $8.68
- Analyst Decision
- UFCS Hold
- ABVX Strong Buy
- Analyst Count
- UFCS 1
- ABVX 5
- Target Price
- UFCS $26.00
- ABVX $39.80
- AVG Volume (30 Days)
- UFCS 114.1K
- ABVX 89.5K
- Earning Date
- UFCS 11-05-2024
- ABVX 09-09-2024
- Dividend Yield
- UFCS 2.34%
- ABVX N/A
- EPS Growth
- UFCS N/A
- ABVX N/A
- EPS
- UFCS 1.94
- ABVX N/A
- Revenue
- UFCS $1,207,451,000.00
- ABVX $9,676,417.00
- Revenue This Year
- UFCS N/A
- ABVX $31.67
- Revenue Next Year
- UFCS $9.19
- ABVX $1,189.66
- P/E Ratio
- UFCS $14.06
- ABVX N/A
- Revenue Growth
- UFCS 10.95
- ABVX 100.87
- 52 Week Low
- UFCS $18.04
- ABVX $8.69
- 52 Week High
- UFCS $27.69
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- UFCS 80.36
- ABVX 26.00
- Support Level
- UFCS $24.62
- ABVX $10.27
- Resistance Level
- UFCS $27.69
- ABVX $10.79
- Average True Range (ATR)
- UFCS 0.98
- ABVX 0.36
- MACD
- UFCS 0.49
- ABVX -0.17
- Stochastic Oscillator
- UFCS 99.83
- ABVX 0.00
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.